Having completed my PhD in molecular cell biology at Uppsala University in 2007, I joined AstraZeneca as a postdoctoral researcher in 2009, which offered a great opportunity to introduce in situ proximity ligation assay (isPLA) on projects within the analgesia and Alzheimer’s disease areas. I successfully established isPLA technology into the company, to strengthen the target validation and show activation of target molecules in human tissue and translatable animal models. In 2011, I joined the RIA IMED unit as a Senior Research Scientist, applying state-of-the-art molecular and visualisation technologies to address questions about the activation of the target/protein of interest. I was then promoted to an Associate Principal Scientist role, where I have been involved in activities including target identification, target validation and patient segmentation approaches. I have been acting as translational science lead, ensuring that translational aspects were considered during project progression, using innovative and creative approaches to overcome obstacles and follow the science.

molecular cell biology